ArticleLife (Basel, Switzerland)2022

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines.

Ricardo Ruiz-Villaverde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.